Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients with a ST-segment Elevation Myocardial Infarction.

The DAPA-STEMI trial is a clinical research study examining the potential benefits of dapagliflozin, a medication known as a sodium-glucose cotransporter 2 inhibitor (SGLT2i), in reducing heart muscle scarring and improving heart function in patients who have experienced a ST-segment elevation myocardial infarction (STEMI). The trial will utilize cardiac MRI to assess changes in heart structure and function over a six-month period. The study aims to offer valuable insights into preventing heart failure following heart attacks. Patients between the ages of 30 and 85 who have recently suffered a STEMI will be randomly assigned to receive either dapagliflozin or a placebo. [Extracted from the article]